The Role of Pharmacotherapy for Excessive Daytime Sleepiness in OSA: A Changing Landscape?
Abstract
Topic importance: Excessive daytime sleepiness is a key presenting feature of patients with OSA. When sleepiness remains despite traditional therapies like CPAP, wakefulness-promoting medication may be appropriate. Treating daytime sleepiness directly also may benefit patients who are unable to tolerate CPAP or other mechanical therapies. The growing number of patients with obesity-related OSA may experience sleepiness caused by both OSA and obesity, and weight loss pharmacotherapy may reduce daytime sleepiness.
Review findings: Several wakefulness promoters are available globally for the indication of residual excessive daytime sleepiness (EDS) in OSA despite CPAP, with some differences in drug access among countries. Recent network meta-analyses have examined the comparative effectiveness of approaches to treat residual EDS in OSA, but clinical guidelines have not been updated since 2013. This review explores the latest evidence on currently available wakefulness promoters and their comparative effectiveness in EDS despite treatment. Evidence for treating sleepiness in the lesser-studied group of patients who are unable to tolerate mechanical therapies for OSA is presented, and the future directions of 2 emerging drug classes are explored, including orexin-2 receptor agonists, with their direct wake-promoting effect, and incretin-based antiobesity agents used in OSA.
Summary: We found that existing medications reduce daytime sleepiness in both patients with EDS despite…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.